(Hypertension. 1999;33:225-231.)
© 1999 American Heart Association, Inc.
Scientific Contribution |
Correspondence to Jorge E. Toblli, MD, PhD, Laboratory of Experimental Medicine, Department of Internal Medicine, Hospital Alemán, Av. Pueyrredon 1640, Buenos Aires (1118) Argentina. E-mail jtoblli{at}pinos.com
| Abstract |
|---|
|
|
|---|
-smooth muscle actin, transforming
growth factor-ß1, and collagen type III were measured.
Rats belonging to the hyperoxaluric group treated with enalapril (G3)
showed fewer tubulointerstitial lesions (1.3±0.2
versus 3±0.2; P<0.01), lower urine albumin
excretion (8±2 mg/d versus 25±2 mg/d; P<0.01), less
percentage of
-smooth muscle actin in renal interstitium (2±0.4%
versus 13.5±2.4%; P<0.01), less percentage of
transforming growth factor-ß1 in
tubulointerstitial area (3.3±1% versus
13.3±2.1%; P<0.01), less percentage of collagen type
III interstitial deposition (0.7±0.5% versus 7±2.6%;
P<0.01), and increased NO production in serum
as well as urine (both P<0.01), when compared with the
hyperoxaluric group not treated with enalapril (G2). Considering these
data, we believe that enalapril, by several mechanisms of action, could
provide an important benefit in the prevention of inflammatory
response, transforming growth factor-ß1
tubulointerstitial production, collagen
type III interstitial deposition, and finally, the
progressive tubulointerstitial fibrosis caused
by oxalates.
Key Words: enalapril hyperoxaluria tubulointerstitial lesions renal fibrosis renin-angiotensin system.
| Introduction |
|---|
|
|
|---|
Fibrosis is caused by a combination of both increased extracellular matrix (ECM) protein synthesis and inhibition of ECM degradation. Interstitial fibrosis is characterized by accumulation of ECM proteins generally found in the interstitium (such as collagen I, collagen III, and fibronectin) and the de novo appearance of ECM proteins such as collagen IV and laminin. Overexpression of protease inhibitors, including the tissue inhibitors of metalloproteinases (TIMP) or plasminogen activator inhibitors (PAI), is the most consistent change in the ECM degradation pathway. Moreover, expression of the fibrogenic cytokine, transforming growth factor-ßl (TGF-ß1), is upregulated. In addition, the interstitium is infiltrated by cells of the monocyte/macrophage lineage. These cells appear to be an important source of TGF-ß1. The fundamental mechanisms involved in the recruitment of circulating monocytes into the interstitium remain largely unknown.2
Numerous studies have reported the relationship between
TGF-ß1 and ECM
production.3 4 It is currently recognized that
TGF-ß1 (1) induces
-smooth muscle actin
expression in mesangial cells; (2) modulates
fibroblast-myofibroblast transformation; (3) stimulates protein
synthesis of types I, III, and V collagen, fibronectin, and
proteoglycans; (4) is upregulated by TIMP; and (5) participates
in apoptotic process.5 In the kidney several cells
express TGF-ß1, such as mesangial
cells, epithelial tubular cells, macrophages, fibroblasts, and
myofibroblasts.
The renin-angiotensin system (RAS) has an important role in the development of TI fibrosis in experimental models, because ACE inhibitors as well as angiotensin II (Ang II) type 1 (AT1) receptor antagonists can reverse it.6 7 8
Hyperoxaluria (Hox) is a well-known cause of renal stone disease and TI damage. In hyperoxaluric states, oxalate accumulates in renal tubular cells and leads to the development of continuous TI inflammation. The purpose of this study was to evaluate the effects of an ACE inhibitor, enalapril (E), on the TI damage produced by Hox.
| Methods |
|---|
|
|
|---|
Blood Pressure Measurement
Systolic blood pressure (SBP) was measured by tail-cuff
plethysmography while rats were quietly restrained in a plastic
chamber. A minimum of 3 measurements was taken at each session, and the
SBP registered was the average of the 3 readings of 3 minutes each.
Biochemical Procedures
Serum and urine creatinine, urine pH, oxalate and
urine albumin concentrations were measured by standard
techniques.8 Nitric oxide (NO) production was
evaluated by measuring plasma and urine nitrite plus nitrate with a
colorimetric assay based on the Greiss
reaction.9
Kidney Processing and Examination
Kidneys were perfused with saline solution through the abdominal
aorta until free of blood. Decapsulated kidneys were cut longitudinally
and fixed in phosphate-buffered 10% formaldehyde (pH 7.2) and embedded
in paraffin. Three-micron sections were cut and stained with
hematoxylin-eosin (H&E), periodic acid-Schiff reagent (PAS), and
Mason's trichrome.
Immunolabeling and Optical Microscopy
Immunolabeling of specimens was carried out by a modified
avidin-biotin-peroxidase complex technique Vectastain ABC kit
(Universal Elite, Vector Laboratories) and the specimens were handled
as described previously.10 11 Renal
-smooth muscle
actin (
-SMA), collagen (COL) III, and TGF-ß1
were quantified with use of anti-mouse
-SMA, clone no. 1A4, lot no.
107F-4806 (Sigma Chemical Co.) monoclonal antibodies; anti-COL III, lot
AM 1670696 (Biogen), and anti-human TGF-ß1 lot
496143 dilution 1: 400 (Chemicon) monoclonal antibodies, with protease
0.1% for 8 minutes and then washing with distillated water.
Morphologic Analysis
Twenty histologic sections were studied in each animal by
an image analyzer (Bioscan-OPTIMAS). Morphologic
analyses were performed with the observer blind to the animal
treatment group. TI lesions were graded: 0=absent; 1=mild.; 2=moderate;
3=severe; or 4=very severe. Sections were evaluated for percentage of:
(1)
-SMA in renal TI; (2) COL III in renal TI; (3)
TGF-ß1 in renal TI.
Statistical Method
Values were expressed as mean±SEM. All statistical
analysis were performed with absolute values and processed
through GraphPad Prism, version 2.0 (GraphPad Software, Inc.). All
comparison among groups was performed by ANOVA. Difference of mean
values between two groups was assessed by the two-tail t
test. A value of P<0.05 was considered significant.
| Results |
|---|
|
|
|---|
|
|
|
Significant (P<0.01) increases in
-SMA and
TGF-ß1 in peritubular and tubular cells and in
interstitial COL III were detected by
immunostaining in rats in G2 (ETG) (Figures 3
, 5
, and 7
and Table 2
). Rats from G3 (ETG+E),
presented small (P<0.01) amounts of
-SMA,
TGF-ß1, and COL III as shown in Figures 4
, 6
, and 8
and Table 2
.
|
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
The mechanism by which hyperoxaluria and increased intracellular
oxalate produce tubular cell damage is unknown. Oxalate is transported
bidirectionally in the tubular cell, and its accumulation inside the
cell produces changes in the activity of several enzymes (eg, lactate
deshydrogenase, malate deshydrogenase, pyruvate
kinase).14 15 Studies with LLC-PK1
cells (a line of renal epithelial cells with characteristics of
proximal tubular cells) revealed that oxalate in a high concentration
acts as a cellular toxin by increasing free-radical
production,16 a process that could be directly
injurious or a catalyst for the start of various inflammation pathways
(Figure 9
).
|
Interstitial inflammation, edema, or fibrosis can impair glomerular arteriolar outflow, lead to increased intraglomerular hypertension, and induce proteinuria.17
Significant cortical renal interstitium increases in COL III
deposition, the earliest collagen type to appear in fibrotic processes,
were seen in G2 (no E treatment). This element of renal fibrosis and
proteinuria were blunted by E administration (Figure 8
; Tables 1
and 2
). These findings suggest that the RAS is involved
in the pathophysiology of hyperoxaluric TI lesions.
Studies in humans and animals indicate that Ang II can induce
TGF-ß1 and alter ECM production by
increasing its deposition.18 19 20 21 Also,
TGF-ß1 inhibits matrix degradation, upregulates
the integrin matrix-adhesion molecules, and leads to chemoattraction of
fibroblasts and monocytes.22 It regulates type I, type
III, and type VI collagen, fibronectin, and laminin23 24 ;
it also influences the transcription of
-SMA, which participates in
the transformation of fibroblast to myofibroblast.25
In a model of urinary tract obstruction, E significantly reduced
the interstitial volume and the amount of renal cortical
collagen.7 Klahr et al3 and Pimentel et
al19 proposed that urinary tract obstruction
activates the RAS and stimulates TGF-ß1
synthesis by tubular epithelial cells. Hyperoxaluric animals in our
study have marked deposition of TGF-ß1 in the
interstitium (Figure 5
and Table 2
). These changes, in
addition to macrophage parenchyma infiltration, can cause renal
tissue progressive fibrosis (Figure 9
).
Hyperoxaluric rats treated with E exhibit a very modest amount of
TGF-ß1 in epithelial tubular cells as well as
in the interstitium (Figure 6
and Table 2
). In the
present studies, obstruction to urine flow because of intratubular
oxalate precipitation may have been one of the mechanisms leading to
interstitial fibrosis and mononuclear cell infiltration.
Mononuclear cells can significantly increase local
TGF-ß1 synthesis. Because E reduced the
intensity of staining for TGF-ß1, our data
suggest that RAS is involved in hyperoxaluric TI fibrosis.
Similar results with ACE inhibition were observed in rats with chronic immune complex nephritis, in which quinapril decreased renal cortical mRNA levels for TGF-ß1, fibronectin, and I, II, and IV collagen.20 ACE inhibition is associated with a significant decrease in monocyte/macrophage infiltration of the kidney with ureteral obstruction.7
Inhibition of ACE may also exert a beneficial effect through its action to increase local amounts of bradykinin. Bradykinin is a potent stimulus for the release of NO,26 which ameliorates the TI lesions caused by ureteral obstruction by reducing monocyte/macrophage infiltration.27 Administration of L-arginine, a precursor of NO, decreases chemoattraction for mononuclear cells in various experimental models.28 In our experiment, a significant increase in NO metabolites (NO2+NO3) in blood and urine was found in hyperoxaluric animals treated with E (G3). Based on these data we suggest that one of the mechanisms involved in protection from TI lesion is NO production.
We also suggest that NO release as a result of treatment with ACE inhibitors may mediate an increase in antioxidant defense levels. Hypoxia as a result of vascular injury, from oxalate overload, can increase the production of reactive oxygen species (ROS). This is supported by the demonstration of in vitro tubular cell damage by oxalate mediated by oxidative stress.16 Cavanagh et al29 found that E and captopril increase antioxidant enzyme levels in various organs of the mouse, including the kidney. This could be another mechanism by which ACE inhibitor protects against oxalate cytotoxicity and against tubular and interstitial injury.
We conclude that E protects the kidney from the TI damage produced by oxalate by reducing Ang II production, TGF-ß1 synthesis and deposition, COL III interstitial deposition, and thus progressive TI fibrosis.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received September 16, 1998; first decision October 12, 1998; accepted October 23, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C. Veena, A Josephine, S. Preetha, and P Varalakshmi Effect of sulphated polysaccharides on erythrocyte changes due to oxidative and nitrosative stress in experimental hyperoxaluria Human and Experimental Toxicology, December 1, 2007; 26(12): 923 - 932. [Abstract] [PDF] |
||||
![]() |
T. Umekawa, Y. Hatanaka, T. Kurita, and S. R. Khan Effect of Angiotensin II Receptor Blockage on Osteopontin Expression and Calcium Oxalate Crystal Deposition in Rat Kidneys J. Am. Soc. Nephrol., March 1, 2004; 15(3): 635 - 644. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Mpofu, J M Rhodes, C M A Mpofu, and R J Moots An unusual cause of acute renal failure in systemic sclerosis Ann Rheum Dis, December 1, 2003; 62(12): 1133 - 1134. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M.V. de Cavanagh, F. Inserra, J. Toblli, I. Stella, C. G. Fraga, and L. Ferder Enalapril Attenuates Oxidative Stress in Diabetic Rats Hypertension, November 1, 2001; 38(5): 1130 - 1136. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |